Market: NMS |
Currency:
Address:
📈 NGEN Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$5.97
-
Upside/Downside from Analyst Target:
-
-
Broker Call:
5
-
Dividend Minimum 3 Year Yield:
-
-
EPS Growth Range (1Y):
0-10%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for NGEN
No earnings history available for this symbol.
📰 Related News & Research
-
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.96 Per Share Plus Contingent Value Rights in 2026 Merger Deal
April 4, 2026
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences: Key ...
-
Gen Digital Inc. (Formerly NortonLifeLock/Symantec) Files Form 8-K Disclosing Common Stock and Contingent Value Rights on NASDAQ
March 28, 2026
Gen Digital Inc. Enters Into Third Amendment to Amended and ...
-
Rezolute Updates on Congenital Hyperinsulinism Program After FDA Meeting; SunRIZE Data Under Review for Potential Advancement 1
March 24, 2026
Rezolute, Inc. Provides Update on Congenital Hyperinsulinism...
-
Antengene Corporation Limited Announces Board Meeting to Approve 2025 Annual Results on March 20, 2026 1
March 10, 2026
Key Highlights Board Meeting Date: Friday, March 20, 2026...
-
enGene Holdings Inc. Q1 2026 Quarterly Report: Financial Statements, Management Discussion & Key Disclosures
March 9, 2026
EnGene Holdings Inc. Q1 2026 Financial Results: Key Details ...
-
enGene Reports Q1 2026 Results, Advances Detalimogene for Bladder Cancer with Strong Cash Position and FDA Milestones 12
March 9, 2026
enGene Holdings Inc. Reports First Quarter 2026 Financial Re...
-
enGene Holdings Inc. Announces Sales Agreement with Leerink Partners LLC for At-the-Market Offering of Common Shares
March 9, 2026
Engene Holdings Inc. – Key Developments in Latest 8-K Filing...
🔍 View more Reports
